Express News | 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law
Cautious Optimism for Design Therapeutics: Hold Rating Amid Promising Phase 1 Results and Extended Development Timeline
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Design Therapeutics (DSGN) and Arvinas Holding Company (ARVN)
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5
Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'
Design Therapeutics Announces Data From Phase 1 SAD/MAD Trial of DT-168
Design Therapeutics Releases Phase 1 Data For DT-168 Supporting Advancement Into Phase 2 Biomarker Trial For Patients With Fuchs Endothelial Corneal Dystrophy
Express News | Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement Into Phase 2 Biomarker Trial for Patients With Fuchs Endothelial Corneal Dystrophy
Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025
Press Release: Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
Bright Peak Therapeutics Appoints John Schmid to Its Board of Directors
Top Premarket Gainers
12 Health Care Stocks Moving In Friday's Pre-Market Session
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Raises Target Price to $5
RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk
Design Therapeutics GAAP EPS of -$0.24
Design Therapeutics | 10-K: FY2024 Annual Report
Design Therapeutics Provides Corporate Highlights, Anticipated Milestones